Camber Capital Management’s Genomic Health, Inc. GHDX Stock Holding History

Camber Capital Management’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,458,100	Closed	-$124M	–	34
2018 Q2	$124M	Hold	2,458,100	–	–	4.77%	5
2018 Q1	$76.9M	Hold	2,458,100	–	–	3.78%	11
2017 Q4	$84.1M	Hold	2,458,100	–	–	4.11%	9
2017 Q3	$78.9M	Hold	2,458,100	–	–	5%	6
2017 Q2	$80M	Hold	2,458,100	–	–	3.9%	8
2017 Q1	$77.4M	Hold	2,458,100	–	–	3.14%	8
2016 Q4	$72.2M	Hold	2,458,100	–	–	3.76%	9
2016 Q3	$71.1M	Hold	2,458,100	–	–	3.13%	12
2016 Q2	$63.7M	Hold	2,458,100	–	–	3.08%	10
2016 Q1	$60.9M	Hold	2,458,100	–	–	3.57%	11
2015 Q4	$86.5M	Buy	2,458,100 +8,100	+0.3%	+$217K	5.59%	3
2015 Q3	$51.8M	Buy	2,450,000 +350,000	+17%	+$9.02M	4.44%	7
2015 Q2	$58.4M	Hold	2,100,000	–	–	3.97%	9
2015 Q1	$64.2M	Sell	2,100,000 -50,000	-2%	-$1.59M	4.58%	5
2014 Q4	$68.7M	Buy	2,150,000 +150,000	+8%	+$4.88M	4.57%	5
2014 Q3	$56.6M	Buy	2,000,000 +275,000	+16%	+$7.67M	5.32%	4
2014 Q2	$47.3M	Buy	1,725,000 +975,000	+130%	+$26M	3.1%	10
2014 Q1	$19.8M	Buy	+750,000	New	+$21.5M	1.55%	23

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Camber Capital Management's GHDX Position: Q3 2018 in Review

Camber Capital Management sold out of Genomic Health, Inc. (GHDX) in Q3 2018, closing a stake of 2,458,100 shares — an estimated $124M sold.

Camber Capital Management first reported a position in GHDX in Q1 2014 and held it in 18 quarters. The position peaked at $124M in Q2 2018. 201 funds tracked by Wall St. Rank hold GHDX as of Q3 2018.

Camber Capital Management reported no remaining Genomic Health, Inc. position as of Q3 2018 after selling out during the quarter.
Camber Capital Management sold 2,458,100 Genomic Health, Inc. shares in Q3 2018, an estimated $124M.
Camber Capital Management first reported a position in Genomic Health, Inc. in Q1 2014 and held it in 18 quarters.
Camber Capital Management's Genomic Health, Inc. position peaked at $124M in Q2 2018.
201 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q3 2018.

Based on Camber Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.